4DMedical Adds UC San Diego Health as Fourth Major U.S. Academic Adopter of CT:VQ

The latest announcement is out from 4DMedical Ltd ( (AU:4DX) ).

4DMedical has secured UC San Diego Health, one of the top-ranked U.S. centres for pulmonology and lung surgery, as the fourth major academic medical centre to deploy its CT:VQ respiratory imaging solution for clinical use. Under an introductory pricing arrangement through March 2026, UC San Diego will integrate CT:VQ into its cardiothoracic imaging program as a high-resolution, contrast-free alternative to traditional nuclear medicine ventilation-perfusion scans. This latest adoption, following earlier deployments at Stanford, the University of Miami and Cleveland Clinic, underscores rapid post-FDA-clearance traction for CT:VQ and strengthens 4DMedical’s strategy of using leading academic institutions as reference sites to drive broader U.S. market uptake and establish its technology as a new standard of care in pulmonary imaging.

The most recent analyst rating on (AU:4DX) stock is a Hold with a A$3.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

More about 4DMedical Ltd

4DMedical Limited (ASX:4DX) is a global medical technology company focused on respiratory imaging, using patented XV Technology to convert standard scans into detailed functional assessments of lung ventilation and perfusion. Its software portfolio, which includes FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS), CT LVAS and the CT:VQ solution, targets earlier and more precise detection, diagnosis and monitoring of lung disease, aiming to set new benchmarks in cardiothoracic imaging.

Average Trading Volume: 4,591,859

Technical Sentiment Signal: Buy

Current Market Cap: A$2.15B

Learn more about 4DX stock on TipRanks’ Stock Analysis page.